Trevena Announces Pricing of Initial Public Offering

04-02-2014 Business Wire HealthComments (0)


Related Companies

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day opt

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top